Changes in lipid profile and markers of metabolic syndrome after 3 years of testosterone-therapy in female-to-male transsexuals

Antonio Becerra; Miriam Menacho; Gilberto Perez-Lopez; Rosa Villar; Rey Jose Manuel Del; Nuria Asenjo; Maria Jesus Lucio; Jose Miguel Rodriguez-Molina; Jose Luis Llopis

doi:10.1530/endoabs.32.P190

P190

Prev Next

Section Contents Cite

Endocrine Abstracts (2013) 32 P190 | DOI: 10.1530/endoabs.32.P190

ECE2013 Poster Presentations Cardiovascular Endocrinology & Lipid Metabolism (41 abstracts)

Changes in lipid profile and markers of metabolic syndrome after 3 years of testosterone-therapy in female-to-male transsexuals

Antonio Becerra ^1, , Miriam Menacho ¹ , Gilberto Perez-Lopez ³ , Rosa Villar ⁴ , Jose Manuel Del Rey ¹ , Nuria Asenjo ¹ , Maria Jesus Lucio ¹ , Jose Miguel Rodriguez-Molina ¹ & Jose Luis Llopis ⁵

Err

Author affiliations

¹Hospital Universitario Ramon y Cajal, Madrid, Spain; ²Universidad de Alcalá, Madrid, Spain; ³Hospital Comarcal de Melilla, Melilla, Spain; ⁴Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain; ⁵Universidad Autonoma, Madrid, Spain.

Introduction: Different studies have published that testosterone therapy in men and women results in decreased HDL cholesterol and increased LDL cholesterol, and therefore an increased cardiovascular risk.

Aims: To determine whether testosterone therapy has this effect on lipid parameters and markers of metabolic syndrome (MetSyn) in female-to-male transsexuals (FMT).

Material and methods: We studied 50 FMT, aged 27.8±7.6 years, at baseline and after 3 years of treatment with testosterone undecanoate (1000 mg/12 weeks, i.m.). None had done gonadectomy. Weight (W), BMI, waist and hip circumference, and systolic and diastolic blood pressure were determined. We also measured plasma levels of glucose, total cholesterol (TC), LDL, HDL, tryglicerides, apolipoprotein A-I (ApoA-I), apolipoprotein B (ApoB), lipoprotein (a) (Lp(a)), homocysteine (Hcy), 25-hydroxy vitamin D3, iron, ferritin, transferrin, total testosterone, estradiol, prolactin, sex hormone-binding globulin, delta 4-androstenedione, dehydroepiandrosterone sulphate, FSH and LH.

Results: After 3-year testosterone-therapy, there was a significant increase in the levels of testosterone (52±26–697±277 ng/dl, P=0.001), TC (166±29–180±33 mg/dl, P=0.031), LDL (97±27–113±27 mg/dl, P=0.027), ApoB (79±20–86±20 mg/dl, P=0.021), iron (74±38–96±47 mg/dl, P=0.031), ferritin (44±25–57±32 mg/dl, P=0.031), and Hcy (10±4–12±3 mg/dl, P=0.012); and a significant decrease of HDL (53±12–47±11 mg/dl, P=0.002), ApoA-I (152±25–135±23 mg/dl, P=0.001), and Lp(a) (24±20–18±20 mg/dl, P=0.041). The other values unchanged significantly.

Conclusion: We conclude that long-term testosterone-therapy in FMT can promote an increased atherogenic by lowering HDL and ApoA-I, and by increasing TC, LDL, ApoB, Hcy, iron, and ferritin levels. But on the other hand, it produces a decrease in Lp(a) and without changing other markers of MetSyn.